TD Cowen lowered the firm’s price target on Novavax (NVAX) to $7 from $8 and keeps a Hold rating on the shares. The firm updated its model ahead of Q3 results to reflect recent industry data and company updates. Positive P1/2 update for NVAX + SNY COVID-19/flu combo is encouraging, although latest U.S. Rx trends suggest declining COVID-19 vaccine market will be near-term headwind.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX: